29 May 2026
18:00 CEST |
IPSEN |
Ipsen announces the launch of an Employee Shareholding Plan
|
20103015 Pharmaceuticals |
Share history |
29 May 2026
18:00 CEST |
IPSEN |
Ipsen annonce le lancement d'une opération d’actionnariat salarié
|
20103015 Pharmaceuticals |
Share history |
28 May 2026
07:30 CEST |
IPSEN |
New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC
|
20103015 Pharmaceuticals |
- |
28 May 2026
07:30 CEST |
IPSEN |
De nouvelles données "late-breaking" renforcent l’impact d’IQIRVO® sur l’ALP, la fatigue et le prurit dans la CBP.
|
20103015 Pharmaceuticals |
- |
27 May 2026
18:30 CEST |
IPSEN |
IPSEN - Buy-back programme - Art 5 of MAR - Week 21 - 2026
|
20103015 Pharmaceuticals |
Share history |
27 May 2026
18:30 CEST |
IPSEN |
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 21 - 2026
|
20103015 Pharmaceuticals |
Share history |
19 May 2026
21:00 CEST |
IPSEN |
Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity
|
20103015 Pharmaceuticals |
- |
19 May 2026
21:00 CEST |
IPSEN |
Ipsen annonce des données « late-breaking » issues de la première étude comparative directe entre Dysport® et Botox® chez des adultes atteints de spasticité du membre supérieur
|
20103015 Pharmaceuticals |
- |
18 May 2026
18:30 CEST |
IPSEN |
Ipsen - Avril 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
18 May 2026
18:30 CEST |
IPSEN |
Ipsen - April 2026- Monthly information relative to the total number of voting rights and shares composing the share capital
|
20103015 Pharmaceuticals |
Share history |
18 May 2026
07:00 CEST |
IPSEN |
Ipsen lance un nouveau programme de rachat d’actions
|
20103015 Pharmaceuticals |
Corporate life |
18 May 2026
07:00 CEST |
IPSEN |
Ipsen initiates a new share buy-back program
|
20103015 Pharmaceuticals |
Corporate life |
16 May 2026
14:00 CEST |
IPSEN |
Ipsen présente les derniers résultats d'une étude de phase II sur la corabotase, première de sa classe, concernant les rides glabellaires, montrant une durée d'effet prolongée et un niveau de satisfaction constamment élevé chez les patients
|
20103015 Pharmaceuticals |
- |
16 May 2026
14:00 CEST |
IPSEN |
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
|
20103015 Pharmaceuticals |
- |
14 May 2026
07:30 CEST |
IPSEN |
Ipsen présente la corabotase, un neuro-inhibiteur recombinant (RNI™) « premier de sa classe », lors du symposium SCALE
|
20103015 Pharmaceuticals |
- |
14 May 2026
07:30 CEST |
IPSEN |
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium
|
20103015 Pharmaceuticals |
- |
13 May 2026
18:15 CEST |
IPSEN |
Annual General Meeting of Ipsen S.A. held on 13 May 2026
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
13 May 2026
18:15 CEST |
IPSEN |
Assemblée Générale Annuelle d’Ipsen S.A. du 13 mai 2026
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
13 May 2026
18:15 CEST |
IPSEN |
Ipsen S.A. – Evolution of the composition of the Board of Directors
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
13 May 2026
18:15 CEST |
IPSEN |
Ipsen S.A. – Evolution de la composition du Conseil d’administration
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
23 Apr 2026
07:00 CEST |
IPSEN |
Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
|
20103015 Pharmaceuticals |
Commercial results |
23 Apr 2026
07:00 CEST |
IPSEN |
Ipsen enregistre une forte croissance de ses ventes au premier trimestre 2026 et confirme ses objectifs annuels
|
20103015 Pharmaceuticals |
Commercial results |
22 Apr 2026
18:00 CEST |
IPSEN |
Ipsen S.A. - Information relating to the holding of the Combined Shareholders’ Meeting of 13 May 2026
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
22 Apr 2026
18:00 CEST |
IPSEN |
Ipsen S.A. - Informations concernant la tenue de l’Assemblée Générale Mixte du 13 mai 2026
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
22 Apr 2026
07:00 CEST |
IPSEN |
Ojemda® approuvé dans l’Union européenne comme première thérapie ciblée pour les enfants atteints de gliome pédiatrique de bas grade (pLGG), en rechute ou réfractaire, indépendamment de l’altération de BRAF
|
20103015 Pharmaceuticals |
- |
22 Apr 2026
07:00 CEST |
IPSEN |
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
|
20103015 Pharmaceuticals |
- |
03 Apr 2026
07:00 CEST |
IPSEN |
Ipsen annonce l’obtention par Beech Tree d’une dérogation à l’obligation de déposer une offre publique
|
20103015 Pharmaceuticals |
Other financial transaction |
03 Apr 2026
07:00 CEST |
IPSEN |
Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer
|
20103015 Pharmaceuticals |
Other financial transaction |
01 Apr 2026
18:00 CEST |
IPSEN |
Ipsen annonce la mise à disposition de son Document d’enregistrement universel 2025
|
20103015 Pharmaceuticals |
Corporate life |
01 Apr 2026
18:00 CEST |
IPSEN |
Ipsen announces the availability of its 2025 Universal Registration Document
|
20103015 Pharmaceuticals |
Corporate life |
18 Mar 2026
07:00 CET |
IPSEN |
Ipsen présente le potentiel transformateur de son pipeline d’immuno oncologie précoce au congrès AACR
|
20103015 Pharmaceuticals |
- |
18 Mar 2026
07:00 CET |
IPSEN |
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
|
20103015 Pharmaceuticals |
- |
13 Mar 2026
18:00 CET |
IPSEN |
Ipsen - February 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
|
20103015 Pharmaceuticals |
Share history |
13 Mar 2026
18:00 CET |
IPSEN |
Ipsen - Février 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
12 Mar 2026
07:30 CET |
IPSEN |
Ipsen appoints Michelle C. Werner as EVP, President of North America
|
20103015 Pharmaceuticals |
- |
09 Mar 2026
18:37 CET |
IPSEN |
Update: Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde
|
20103015 Pharmaceuticals |
Products and services |
09 Mar 2026
18:37 CET |
IPSEN |
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
|
20103015 Pharmaceuticals |
Products and services |
09 Mar 2026
07:00 CET |
IPSEN |
Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde
|
20103015 Pharmaceuticals |
- |
09 Mar 2026
07:00 CET |
IPSEN |
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
|
20103015 Pharmaceuticals |
- |
27 Feb 2026
12:20 CET |
IPSEN |
Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF
|
20103015 Pharmaceuticals |
- |
27 Feb 2026
12:20 CET |
IPSEN |
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
|
20103015 Pharmaceuticals |
- |
19 Feb 2026
10:26 CET |
IPSEN |
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
|
20103015 Pharmaceuticals |
Corporate life |
19 Feb 2026
10:26 CET |
IPSEN |
Ipsen S.A. publie ses comptes consolidés 2025
|
20103015 Pharmaceuticals |
Corporate life |
12 Feb 2026
07:00 CET |
IPSEN |
Ipsen réalise de solides résultats en 2025, grâce à une performance soutenue de toutes les aires thérapeutiques, et annonce ses objectifs 2026
|
20103015 Pharmaceuticals |
Commercial results |
12 Feb 2026
07:00 CET |
IPSEN |
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
|
20103015 Pharmaceuticals |
Commercial results |
09 Feb 2026
18:30 CET |
IPSEN |
Ipsen - Janvier 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
09 Feb 2026
18:30 CET |
IPSEN |
Ipsen - January 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
|
20103015 Pharmaceuticals |
Share history |
29 Jan 2026
07:00 CET |
IPSEN |
Ipsen nominates Peter Guenter to its Board of Directors
|
20103015 Pharmaceuticals |
Journal / appointments |
29 Jan 2026
07:00 CET |
IPSEN |
Ipsen nomme Peter Guenter au sein de son Conseil d’Administration
|
20103015 Pharmaceuticals |
Journal / appointments |
27 Jan 2026
07:00 CET |
IPSEN |
Pierrick Lefranc nommé Vice-Président Exécutif Opérations Techniques et membre du Comité Exécutif
|
20103015 Pharmaceuticals |
Journal / appointments |